ASArtemii M. Savin

Artemii M. Savin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Artemii M. Savin has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Strain-Dependent Effects of Azurin-Producing Probiotic Escherichia coli on HCT116 Colorectal Carcinoma Cells

    by Nairouz Deeb, Georgy Otinov, Alexey Tikhomirov, Ellen Mouhammad, Artemii Savin, Elena Koshel

    Probiotic bacteria are increasingly being explored as engineering platforms for local production of bioactive proteins, but the outcome may depend on both the recombinant protein and the bacterial strain. Azurin-producing derivatives of Escherichia coli Nissle 1917 (EcN) and E. coli M17 were generated using the same lacUV5-pelB-azu cassette and evaluated in HCT116 colorectal carcinoma cells. Western blotting confirmed azurin production in both strains, predominantly in cell-associated fractions and at lower levels in concentrated culture supernatants. A separately produced recombinant azurin preparation obtained from E. coli NiCo21(DE3) reduced HCT116 cell biomass after 48 h, with an estimated IC50 of 320 µg/mL. In bacterial co-culture, the azurin-producing derivatives showed lower mean SRB-assessed HCT116 biomass than their corresponding wild-type strains, but these differences did not reach statistical significance. In contrast, YO-PRO-1/PI analysis at a bacteria-to-cell ratio of 500 identified a significant overall increase in the total apoptosis-associated fraction in the azurin-producing groups, whereas the necrosis-associated fraction remained low. The overall response was strain-dependent: EcN showed strong baseline inhibitory activity, whereas the lower baseline effect of M17 allowed the azurin-associated contribution to be distinguished more clearly. Thus, both strains supported recombinant azurin production, but the host–cell response was strongly influenced by the bacterial background. These findings highlight strain selection as an important factor in the development and evaluation of engineered probiotic systems for bioactive protein production.

  • CDK8/19 Inhibition Attenuates the Tolerance of Leukemia Cells to BCR-ABL1 Blockers in the Medium Conditioned by Bone Marrow Fibroblasts

    by A. M. Savin, D. P. Levchuk, A. S. Ilchenko, E. S. Ivanova, A.A. Shtil

    Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 have transformed the treatment of chronic myelogenous leukemia (CML) and other malignancies, including FLT3-ITD-positive acute myelogenous leukemia (AML). However, soluble factors produced by the bone marrow microenvironment can attenuate the cytotoxic response to TKIs. CDK8 and CDK19 are mediator-associated kinases involved in stimulus-induced transcriptional programs, thereby representing plausible targets for limiting the adaptive drug tolerance. Here, we used HS-5 bone marrow fibroblast-conditioned medium as a model of soluble niche support and examined its effects in K562 CML and MV4.11 AML-cells treated with catalytic BCR-ABL inhibitors (imatinib, dasatinib, vamotinib, and olverembatinib) or with the allosteric blocker asciminib. In K562 cells, the conditioned medium reproducibly diminished TKI-induced accumulation of subG1 nuclei, indicating an attenuated DNA fragmentation. YO-PRO-1/propidium iodide staining further showed a redistribution from terminal cell damage by a short-term (72 h) treatment. Protective effects remained sustained for at least 9 days of intermittent exposure to TKI. Two structurally distinct, minimally cytotoxic CDK8/19 inhibitors senexin B (SenB) and SNX631, enhanced TKI-induced cell death in both regular and conditioned media. In MV4.11 cells, SenB and SNX631 increased the cytotoxicity of olverembatinib preferentially in the conditioned medium. Together, these data support a model in which soluble fibroblast-derived factor(s) delay the execution of TKI-induced cell death, while CDK8/19 inhibition antagonizes this adaptive response and restores TKI efficacy under bone marrow-mimicking conditions.


  • Open Access

    The Complex of Copper (II) and Zoledronic Acid: Relevance to Oxidative Death of Leukemia Cells in the Bone Marrow

    by Elena S. Barskaya, Artemii M. Savin, Kirill V. Chernov, Albina S. Petrova, Maksim S. Abramovich, Yulia A. Maksimova, Alexander S. Dubenskiy, Sergey A. Tsymbal, Anna V. Lantsova, Anna A. Moiseeva, et al.

    Copper–organic compounds are being investigated as antitumor candidates. Besides their efficacy as cytotoxic agents alone, the oxidative potential of electrochemical Cu2+-to-Cu1+ transition emerges as an attractive approach for elimination of tumor cells otherwise resistant to chemotherapy. To minimize side effects of the potent oxidative burst upon Cu(II) reduction, the metal cations should be delivered to the tumor site. Taking advantage of the ability of bisphosphonates to accumulate in the bone, we synthesized a Cu(II) complex of zoledronic acid (ZA), an FDA-approved drug for prevention of bone destruction. The CuZA complex obtained upon precipitation of ZA and different copper salts (sulfate, chloride or perchlorate) were structurally identical, consisting of two organic moieties coordinated by three metal cations. Combined treatment with water-soluble formulations of CuZA and cysteine triggered rapid death in human cell lines. This effect was achievable with non-toxic concentrations of CuZA and cysteine alone. Importantly, the K562 chronic myelogenous leukemia cells that demonstrated an attenuated response to the 3d generation Bcr-Abl tyrosine kinase inhibitor in the medium conditioned by bone marrow-derived fibroblasts, were readily killed by CuZA–cysteine combination. Thus, oxidative burst upon metal reduction in CuZA complexes emerges as a promising method of eradication of tumor cells in the bone microenvironment.


  • Open Access

    New Complexes of Copper (II) and Zoledronic Acid: Relevance to Oxidative Death of Leukemia Cells in the Bone Marrow

    by Elena S. Barskaya, Artemii M. Savin, Kirill V. Chernov, Albina S. Petrova, Maksim S. Abramovich, Yulia A. Maksimova, Alexander S. Dubenskiy, Sergey A. Tsymbal, Anna V. Lantsova, Anna A. Moiseeva, et al.

    Copper-organic compounds are being investigated as antitumor candidates. Besides their efficacy as cytotoxic agents alone, the oxidative potential of electrochemical Cu2+-to-Cu1+ transition emerges as an attractive approach for elimination of tumor cells otherwise resistant to chemotherapy. To minimize side effects of the potent oxidative burst upon Cu(II) reduction, the metal cations should be delivered to the tumor site. Taking advantage of the ability of bisphosphonates to accumulate in the bone, we synthesized Cu(II) complexes of zoledronic acid (ZA), an FDA-approved drug for prevention of bone destruction. New CuZA complexes obtained upon precipitation of ZA and different copper salts were structurally identical, consisting of two organic moieties coordinated by three metal cations. Combined treatment with water-soluble formulations of CuZA and cysteine triggered rapid death in human cell lines. This effect was achievable with non-toxic concentrations of CuZA and cysteine alone. Importantly, the K562 chronic myelogenous leukemia cells that demonstrated an attenuated response to the 3d generation Bcr-Abl tyrosine kinase inhibitor in the medium conditioned by bone marrow-derived fibroblasts, were readily killed by CuZA-cysteine combination. Thus, oxidative burst upon metal reduction in CuZA complexes emerges as a promising method of eradication of tumor cells in the bone microenvironment.